Biowaiver for Immediate and Modified Release Dosage forms Scientific summary of the CSPS workshop
A joint Canadian Society for Pharmaceutical Sciences and Health Canada workshop entitled “Biowaiver for Immediate and Modified Release Dosage forms” was held in Ottawa, November 19th 2015. A summary of all presentations is included.
Main Author: | Raimar Loebenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Canadian Society for Pharmaceutical Sciences
2020-08-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31424 |
Similar Items
-
Efficient Estimation of Exposure for Immediate Release Solid Oral Dosage Forms: Biowaiver Considerations for Metformin
by: Chiung-YiChiu, et al.
Published: (2014) -
Gliclazide: Biopharmaceutics Characteristics to Discuss the Biowaiver of Immediate and Extended Release Tablets
by: Bruna de Carvalho Mapa, et al.
Published: (2020-10-01) -
The Requirements for Additional Strength Biowaivers for Immediate Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities
by: Christopher Crane, et al.
Published: (2020-08-01) -
Biopharmaceutics classification system (BCS)-based biowaiver for immediate release solid oral dosage forms of moxifloxacin hydrochloride (Moxiflox GPO) manufactured by the Government Pharmaceutical Organization (GPO)
by: Nawaphon Saelim, et al.
Published: (2016-02-01) -
The design and manufacture of immediate-release optimal solid dosage forms
by: Blaesi, Aron H
Published: (2016)